Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe M OrkinJonathan M SchapiroCarlo F PernoDaniel R KuritzkesParul PatelRebecca DeMoorDavid DoreyYongwei WangKelong HanVeerle Van EygenHerta CrauwelsSusan L FordChristine L LathamMarty St ClairJoseph W PolliSimon VanveggelKati VandermeulenRonald D'AmicoHarmony P GargesAndrew ZolopaWilliam R SpreenJean van WykAmy G CutrellPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
The presence of ≥2 baseline factors (RPV RAMs, A6/A1 subtype, and/or BMI ≥30 kg/m2) was associated with increased CVF risk, consistent with prior analyses. Inclusion of initial model-predicted CAB/RPV trough concentrations (≤1st quartile) did not improve the prediction of CVF beyond the presence of a combination of ≥2 baseline factors, reinforcing the clinical utility of the baseline factors in the appropriate use of CAB + RPV LA.